Arch Therapeutics Receives Clearance to Initiate Clinical Trial in Europe
December 16, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Dec 16, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™...
Arch Therapeutics Receives Notice of Allowance for New Patent in the United States
December 03, 2015 16:02 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Dec 3, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Reports Significant Wound Healing Results in Pre-Clinical Safety Study with AC5 Surgical Hemostatic Device(TM)
December 01, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Dec 1, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), reports that use of its AC5 Surgical Hemostatic Device™ resulted in normal wound...
Arch Therapeutics to Present at the LD Micro Main Event on December 2, 2015
November 25, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Nov 25, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Will Present at Salomon Bio Investment & Leadership Conference
November 11, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Nov 11, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), today...
Arch Therapeutics Will Present at the 2015 Aegis Capital Growth Conference in Las Vegas, NV October 7-9th, 2015
October 07, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 7, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), today announced...
Arch Therapeutics Obtains Additional Positive Safety Data for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Test of Sensitization
September 08, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 8, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), obtained...
Arch Therapeutics Will Present 17th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2015
August 26, 2015 09:10 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 26, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"),...
Arch Therapeutics Appoints James Sulat to Board of Directors
August 20, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 20, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), has appointed...
Arch Therapeutics Announces Private Placement
July 01, 2015 08:18 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jul 1, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), is pleased...